Related Experiment Video
Updated: Aug 17, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Thalidomide in cancer medicine
V Eleutherakis-Papaiakovou1, A Bamias, M A Dimopoulos
1Department of Clinical Therapeutics, University of Athens, School of Medicine, Athens, Greece.
Abstract:
Thalidomide, an oral agent with antiangiogenic and immunomodulatory properties, is being investigated extensively in the management of advanced cancer. Multiple studies with large numbers of patients have confirmed that this drug has significant activity in multiple myeloma. Some patients with myelofibrosis or myeodysplatic syndromes may reduce their need for transfusions after thalidomide treatment. The activity of thalidomide in solid tumors is less prominent. Studies in Kaposi's sarcoma, malignant melanoma, renal cell carcinoma and prostate cancer appear more promising especially when thalidomide is combined with biological agents or with chemotherapy. Limited activity was demonstrated in patients with glioma, while thalidomide appears to be inactive in patients with head and neck cancer, breast or ovarian cancer.
Related Concept Videos
Drugs that Stabilize Microtubules
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Teratogenicity
Therapeutic Drug Monitoring: Affecting Factors

